Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Thomas, C. P. Articles by Ritter, G. A. Search for Related Content PubMed Citation Articles by Thomas, C. P. Articles by Ritter, G. A. Opioids Quality of Care, Practice Guidelines Other Somatic Therapy Related Article

Use of Buprenorphine for Addiction Treatment: Perspectives of Addiction Specialists and General Psychiatrists

The authors are affiliated with the Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, 415 South St., MS035, Waltham, MA 02454-9110 (e-mail: cthomas{at}brandeis.edu).

OBJECTIVE: In 2002 buprenorphine (Suboxone or Subutex) was approved by the U.S. Food and Drug Administration for office-based treatment of opioid addiction. The goal of office-based pharmacotherapy is to bring more opiate-dependent people into treatment and to have more physicians address this problem. This study examined prescribing practices for buprenorphine, including facilitators and barriers, and the organizational settings that facilitate its being incorporated into treatment. METHODS: Addiction specialists and other psychiatrists in four market areas were surveyed by mail and Internet in fall 2005 to examine prescribing practices for buprenorphine. Respondents included 271 addiction specialists (72% response rate) and 224 psychiatrists who were not listed as addiction specialists but who had patients with addictions in their practice (57% response rate). RESULTS: Three years after approval of buprenorphine for office-based addiction treatment, nearly 90% of addiction specialists had been approved to prescribe it and two-thirds treated patients with buprenorphine. However, fewer than 10% of non-addiction specialist psychiatrists prescribed it. Regression-adjusted factors predicting prescribing of buprenorphine included support of training and use of buprenorphine by the physician's main affiliated organization, less time in general psychiatry compared with addictions treatment, more time in group practice rather than solo, ten or more opiate-dependent patients, belief that drugs play a large role in addiction treatment, and patient demand. CONCLUSIONS: Office-based pharmacotherapy offers a promising path to improved access to addictions treatment, but prescribing has expanded little beyond the addiction specialist community.

Related Article:

August 2008: This Month's Highlights
Psychiatr Serv 2008 59: 835. [Full Text] [PDF]

This article has been cited by other articles:

				A.K. Nandakumar, J. Beswick, C. P. Thomas, S. S. Wallack, and D. Kress Pathways Of Health Technology Diffusion: The United States And Low-Income Countries Health Aff., July 1, 2009; 28(4): 986 - 995. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us